Infinimmune Raises $12 Million in Seed Funding
“Infinimmune combines a world-class team of technologists with a state-of-the-art platform for the discovery, characterization, and validation of truly human antibodies,” said Eddie Eltoukhy, Partner at Pear VC.
$12-Million Seed Funding to Design Drugs Using Human-Sourced Antibodies
Early-stage biotechnology company Infinimmune, which is developing novel techniques for antibody drug discovery and development, announced that it has closed a $12-million seed round led by Playground Global, with participation from Pear VC, Civilization Ventures, and Axial VC and support from Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.
Infinimmune’s secret for building better antibody drugs: You
San Francisco Business Times: An East Bay startup is looking to create antibody drugs at the source: humans. Infinimmune, with six people and a fresh $12 million seed round, is made up of veterans of 10x Genomics Inc., the Pleasanton-based company that pioneered single-cell sequencing technology. But the startup’s founders want to turn those types of tools into an engine for finding and developing drugs made from human antibodies.
Spotlight on Infinimmune
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system.
Founding Infinimmune and Developing Breakthrough Tools for Antibody Discovery
Episode Description:
In our conversation with Wyatt McDonnell, the Co-Founder and CEO of Infinimmune, we discuss his journey to 10X Genomics, his work there, and the founding of Infinimmune